Steven Kelly is an experienced biotechnology executive with more than 30 years of leadership across oncology drug development, commercialization, and company building. Prior to joining Actithera, Steve served as President and CEO of Carisma Therapeutics, where he led the company’s evolution from an academic platform to a publicly traded, clinical-stage biotechnology company, raising more than $300 million in financing and establishing collaborations with leading global biopharmaceutical companies. He previously held leadership roles at Theracrine, Innovive Pharmaceuticals, BioVex, Sanofi, IDEC Pharmaceuticals, and Amgen. His extensive experience building and leading biotechnology companies will guide Actithera as it advances its lead program into the clinic and expands its radioligand therapy pipeline.